Jeff Yass’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-24,060
Closed -$10.8K 14145
2022
Q4
$10.8K Sell
24,060
-25,529
-51% -$10.6K ﹤0.01% 11926
2022
Q3
$24K Buy
49,589
+2,725
+6% +$1.34K ﹤0.01% 12544
2022
Q2
$23K Buy
46,864
+16,984
+57% +$8.22K ﹤0.01% 12337
2022
Q1
$18K Buy
29,880
+8,908
+42% +$4.67K ﹤0.01% 12659
2021
Q4
$14K Sell
20,972
-27,127
-56% -$48.4K ﹤0.01% 12892
2021
Q3
$165K Buy
+48,099
New +$150K ﹤0.01% 11709
2021
Q1
Sell
-32,253
Closed -$254K 13041
2020
Q4
$254K Buy
+32,253
New +$296K ﹤0.01% 9611

Other funds holding MTCR

Jeff Yass's MTCR Position: Q1 2023 in Review

Jeff Yass sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 24,060 shares — an estimated $10.8K sold.

Jeff Yass first reported a position in MTCR in Q4 2020 and held it in 7 quarters. The position peaked at $254K in Q4 2020. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Jeff Yass reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Jeff Yass sold 24,060 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $10.8K.
  • Jeff Yass first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • Jeff Yass's Metacrine, Inc. Common Stock position peaked at $254K in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.